CN109485896A - 一种改性聚醚醚酮的制备方法和用途 - Google Patents
一种改性聚醚醚酮的制备方法和用途 Download PDFInfo
- Publication number
- CN109485896A CN109485896A CN201811345142.6A CN201811345142A CN109485896A CN 109485896 A CN109485896 A CN 109485896A CN 201811345142 A CN201811345142 A CN 201811345142A CN 109485896 A CN109485896 A CN 109485896A
- Authority
- CN
- China
- Prior art keywords
- group
- ketone
- sand paper
- test specimen
- modified polyether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004696 Poly ether ether ketone Substances 0.000 title claims abstract description 95
- 229920002530 polyetherether ketone Polymers 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 74
- 238000006277 sulfonation reaction Methods 0.000 claims abstract description 19
- 238000005498 polishing Methods 0.000 claims description 33
- 244000137852 Petrea volubilis Species 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229910017604 nitric acid Inorganic materials 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 22
- 239000011148 porous material Substances 0.000 abstract description 18
- 239000007943 implant Substances 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- -1 phosphonium ion Chemical class 0.000 abstract description 7
- 239000002356 single layer Substances 0.000 abstract description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 6
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 6
- 102000009123 Fibrin Human genes 0.000 abstract description 4
- 108010073385 Fibrin Proteins 0.000 abstract description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 4
- 229950003499 fibrin Drugs 0.000 abstract description 4
- 210000000963 osteoblast Anatomy 0.000 abstract description 4
- 229910006069 SO3H Inorganic materials 0.000 abstract description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 abstract description 3
- 239000002801 charged material Substances 0.000 abstract description 3
- 230000021615 conjugation Effects 0.000 abstract description 3
- 239000000835 fiber Substances 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 3
- 238000001179 sorption measurement Methods 0.000 abstract description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract description 3
- 230000001546 nitrifying effect Effects 0.000 abstract description 2
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 238000012545 processing Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 4
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 4
- 102000004264 Osteopontin Human genes 0.000 description 4
- 108010081689 Osteopontin Proteins 0.000 description 4
- 102000003970 Vinculin Human genes 0.000 description 4
- 108090000384 Vinculin Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229910001069 Ti alloy Inorganic materials 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000001243 pseudopodia Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101900253678 Vinculin (isoform 1) Proteins 0.000 description 1
- 102300041331 Vinculin isoform 1 Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
- C08J7/14—Chemical modification with acids, their salts or anhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2361/00—Characterised by the use of condensation polymers of aldehydes or ketones; Derivatives of such polymers
- C08J2361/04—Condensation polymers of aldehydes or ketones with phenols only
- C08J2361/16—Condensation polymers of aldehydes or ketones with phenols only of ketones with phenols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及医疗技术领域,尤其是一种改性聚醚醚酮的制备方法和用途。本发明的一种改性聚醚醚酮的制备方法通过磺化后硝化在PEEK表面形成孔径大小200nm‑300nm的单层孔状结构,纳米、亚微米级的材料表面形貌作为内在生物信息促进成骨细胞的粘附从而有利于新骨的生成;引入新基团SO3H基团和NO2基团与苯环直接相连,这些基团具有诱导和共轭效应,苯环上的π电子云被转移到基团上,芳烃的主链具有正电荷,支链基团具有负电荷,当植入体进入体内时血液中的水分子、蛋白、钙离子或磷离子首先吸附到材料表面,而带负电荷的材料表面更容易促使钙离子、磷离子及带正电荷的蛋白吸附于材料表面,有利于血小板的粘附加速纤维蛋白凝块的形成及内容物的释放。
Description
技术领域
本发明涉及医疗技术领域,尤其是一种改性聚醚醚酮的制备方法和用途。
背景技术
快速愈合以及稳定的生物安全性是选择植入材料的首要标准。传统的生物材料如钛及钛合金等具有优良的耐腐蚀性,较高的机械强度及较好的生物相容性,但是这类材料弹性模量较高,与人体骨骼应力匹配不足,不耐体液微腐蚀进而释放金属离子,引发细胞毒性反应的发生。目前尚未出现较好地替代材料。
聚醚醚酮(PEEK)作为传统植入材料的替代品已在口腔科和骨科领域引起了广泛关注。PEEK具有优良的力学性能,其弹性、刚度、抗拉强度、抗变形等均在适宜范围内,可与人体骨共存,PEEK的化学稳定性较好,可避免因体液酸碱腐蚀而发生降解,另外,PEEK(4-5Gpa)的弹性模量与人皮质骨(18Gpa)较为接近,避免应力遮蔽反应的发生。因此PEEK广泛应用于脊柱融合术、关节置换术,同时也逐渐成为口腔医学领域的一种新兴潜在的植入材料。
然而,由于PEEK材料的生物惰性以及成骨能力不佳限制了其在口腔领域的应用。如何提高植入体与周围自然骨组织的整合能力,使材料表面改性既可保留基底材料大部分的优势性能,又可构建生物活性涂层。是本领域技术人员亟待解决的技术问题。目前解决这一问题最主要的方法是材料表面改性。孔隙结构尤其是纳米级孔隙可为材料表面细胞提供一个有利的局部微环境,改善细胞/骨-种植体之间的相互作用。为了获得PEEK表面孔隙结构,部分研究通过熔融挤出技术获得微米级孔隙结构,研究证明微米孔PEEK材料的成骨活性明显提高同时也保持了材料承重结构的完整性;另一些研究通过磺化作用获得复杂的三维网状孔隙结构的PEEK表面,研究发现处理后材料表面的生物活性明显提高。然而,部分学者发现较大较复杂的孔隙结构可能会导致深层孔隙内细胞缺乏氧气及营养物质的缺乏,促使不良反应的发生,而较小的孔隙结构可避免这一反应的发生。PEEK的化学结构较稳定,在没有其他表面活性物质如钛、钽、羟基磷灰石等加入时,较难在PEEK表面形成形孔隙结构,尤其是单层的孔隙结构。
发明内容
本发明的目的在于提供一种改性聚醚醚酮的制备方法和用途,克服前述现有技术的不足,制得的聚醚醚酮表面形成直径约为200-300纳米大小的单层纳米孔状结构。
本发明解决其技术问题所采取的技术方案是:一种改性聚醚醚酮的制备方法,包括如下步骤:
(1)将医用级的聚醚醚酮材料制成10mm×10mm×1.0mm/15mm×15mm×1.0mm的方形试件或直径为2mm×5mm的柱状试件,依次用600#、800#、1000#、1200#、1500#、2000#、3000#、5000#、7000#的SiC砂纸逐级打磨、抛光;
(2)将步骤(1)中打磨、抛光后的试件依次用丙酮、无水乙醇、去离子水进行超声清洗10min,用烘干仪干燥10-15min,自然将至室温;
(3)将步骤(2)中干燥后自然降至室温的试件放入采用磁力搅拌器搅拌的浓硫酸中反应5-8min,得到磺化的聚醚醚酮SP试件;
(4)将步骤(3)中磺化的聚醚醚酮SP试件取出放入硝酸中,于16℃下反应50s,得到磺化后硝化的聚醚醚酮试件NP;
(5)将步骤(4)中制得的聚醚醚酮NP试件放入去离子水中浸泡5min,然后再将其放入100℃下的水中,水浴浸泡4h,即得改性聚醚醚酮;
上述步骤中聚醚醚酮改性过程的反应方程如下:
优选的,所述步骤(1)中依次用600#SiC砂纸打磨30s、800#SiC砂纸打磨50s、1000#SiC砂纸打磨70s、1200#SiC砂纸打磨90s、1500#SiC砂纸打磨110s、2000#SiC砂纸打磨130s、3000#SiC砂纸打磨150s、5000#SiC砂纸打磨170s、7000#的SiC砂纸打磨190s。
优选的,所述步骤(2)中丙酮、无水乙醇、去离子的用量均为每个试件1ml。
优选的,所述步骤(3)中浓硫酸的浓度为95-98%,浓硫酸用量为20ml。
优选的,所述步骤(4)中硝酸的浓度为78-84%,硝酸的用量为20ml。
一种改性聚醚醚酮的制备方法制得的改性聚醚醚酮在口腔科和骨科植入材料领域的用途。
本发明通过磺化后硝化在PEEK表面形成孔径大小200nm-300nm的单层孔状结构,孔隙结构可以提高种植体与骨之间生物锁合作用,改善骨/种植体界面,对加速骨愈合、提高植入体的初期稳定性有重要意义。PEEK作为优质的骨植入材料,孔隙结构可加速骨愈合提高其生物性能。
本发明改性过程中PEEK材料产生不同的表面形貌:最初PEEK相对较光滑的材料表面、磺化后硝化制得的NP试件的单层纳米孔隙结构的材料表面。孔隙结构可增加材料比表面积,增大材料总表面积,有利于蛋白质及细胞的粘附。纳米、亚微米级的材料表面形貌可作为内在生物信息促进成骨细胞的粘附从而有利于新骨的生成。这种结构与体内环境较为相似,促进细胞生物功能活性。
本发明制得的改性聚醚醚酮的硝基以及磺酸基团位于PEEK主链之中,未见明显的细胞毒性反应的发生。引入新基团SO3H基团和NO2基团与苯环直接相连,这些基团具有诱导和共轭效应,苯环上的π电子云被转移到基团上,芳烃的主链具有正电荷,支链基团具有负电荷。骨整合的过程涉及复杂的事件序列,当植入体进入体内时血液中的水分子、蛋白、钙离子或磷离子首先吸附到材料表面,而带负电荷的材料表面更容易促使钙离子、磷离子及带正电荷的蛋白吸附于材料表面,从而有利于血小板的粘附加速纤维蛋白凝块的形成及内容物的释放。而纤维蛋白凝块是一个不成熟的孔网状结构,可促使细胞向植入体表面迁移。纤维蛋白凝块网孔状结构建立牢固后,骨重建即开始发生,破骨细胞的吸收和新骨的生成。
本发明的有益效果是:与现有技术相比,本发明的一种改性聚醚醚酮的制备方法过程简单,通过磺化后硝化在PEEK表面形成孔径大小200nm-300nm的单层孔状结构,孔隙结构可增加材料比表面积,增大材料总表面积,有利于蛋白质及细胞的粘附;纳米、亚微米级的材料表面形貌可作为内在生物信息促进成骨细胞的粘附从而有利于新骨的生成;引入新基团SO3H基团和NO2基团与苯环直接相连,这些基团具有诱导和共轭效应,苯环上的π电子云被转移到基团上,芳烃的主链具有正电荷,支链基团具有负电荷,当植入体进入体内时血液中的水分子、蛋白、钙离子或磷离子首先吸附到材料表面,而带负电荷的材料表面更容易促使钙离子、磷离子及带正电荷的蛋白吸附于材料表面,有利于血小板的粘附加速纤维蛋白凝块的形成及内容物的释放;本发明制得的改性聚醚醚酮能够应用于口腔种植领域。
附图说明
图1为本发明SEM下PEEK和NP组材料表面形貌图;
图2为本发明AFM下PEEK和NP组材料表面三维形貌图;
图3为本发明接触角测量仪对PEEK和NP组材料的亲疏水性进行表征结果图;
图4为本发明PEEK和NP组材料的傅立叶变换红外光谱图;
图5为本发明bmscs培养1,4,7,14d增殖检测图;
图6为本发明SEM下bmscs培养4h的形貌图;
图7为本发明bmscs培养4h后DAPI染色图;
图8为本发明bmscs培养4h后DAPI染色定量图;
图9为本发明CLSM下bmscs培养2h、4h、24h图;
图10为本发明bmscs培养2.4h后Vinculin蛋白表达图;
图11为本发明bmscs培养7d、14d碱性磷酸酶染色图;
图12为本发明bmscs培养7d、14d碱性磷酸酶染色染色定量图;
图13为本发明bmscs培养21d茜素红染色图;
图14为本发明bmscs培养21d茜素红染色定量图;
图15为本发明bmscs培养7,14d相关成骨基因的表达检测图;
图16为本发明bmscs培养7,14d相关成骨蛋白的表达图;
图17为本发明MicroCT大鼠体内不同植入体周围新生骨体积图;
图18为本发明大鼠体内不同植入体周围新生骨硬组织切片图;
具体实施方式
实施例1一种改性聚醚醚酮的制备方法
一种改性聚醚醚酮的制备方法,包括如下步骤:
(1)将医用级的聚醚醚酮材料制成10mm×10mm×1.0mm/15mm×15mm×1.0mm的方形试件或直径为2mm×5mm的柱状试件,依次用600#SiC砂纸打磨30s、800#SiC砂纸打磨50s、1000#SiC砂纸打磨70s、1200#SiC砂纸打磨90s、1500#SiC砂纸打磨110s、2000#SiC砂纸打磨130s、3000#SiC砂纸打磨150s、5000#SiC砂纸打磨170s、7000#的SiC砂纸打磨190s,抛光;
(2)将步骤(1)中打磨、抛光后的试件依次用丙酮、无水乙醇、去离子水进行超声清洗10min,丙酮、无水乙醇、去离子的用量均为每个试件1ml,清洗完成后用烘干仪干燥10-15min,自然将至室温;
(3)将步骤(2)中干燥后自然降至室温的试件放入采用磁力搅拌器搅拌的浓硫酸中反应5-8min,浓硫酸的浓度为95-98%,浓硫酸用量为20ml,得到磺化的聚醚醚酮SP试件;
(4)将步骤(3)中磺化的聚醚醚酮SP试件取出放入硝酸中,于16℃下反应50s,硝酸的浓度为78-84%,硝酸的用量为20ml,得到磺化后硝化的聚醚醚酮试件NP;
(1)将步骤(4)中制得的聚醚醚酮NP试件放入去离子水中浸泡5min,然后再将其放入100℃下的水中,水浴浸泡4h,即得改性聚醚醚酮。
实验例1材料表征
将原始的PEEK材料与实施例1中制得的NP材料分为两组,分别为:对照组(PEEK)、磺化后硝化组(NP),利用场发射扫描电子显微镜、原子力显微镜、能谱仪、接触角测量仪以及傅里叶红外仪对PEEK组和NP组实验材料进行表征,通过场发射扫描电子显微镜和原子力显微镜观察磺化、硝化处理前后的材料表面形貌结构,imageJ检测材料表面孔隙大小;利能谱仪进行材料表面元素分布进行表征;通过接触角测量仪对材料的亲疏水性进行表征;利用傅里叶红外仪对材料新引入的官能团进行表征。
场发射扫描电子显微镜下PEEK和NP组材料表面形貌如图1所示,从图中可以看出,PEEK组材料表面相对光滑,imageJ检测后发现硝化处理的NP组材料表面具有孔隙大小为200nm-300nm之间的单层孔状结构,孔隙结构可增加材料比表面积,增大材料总表面积,有利于蛋白质及细胞的粘附,纳米、亚微米级的材料表面形貌可作为内在生物信息促进成骨细胞的粘附从而有利于新骨的生成。
原子力显微镜下PEEK和NP组材料表面三维形貌如图2所示,从图中可以看出,PEEK组表面光滑粗糙度较小;NP组表面孔隙较小有规则,较粗糙。
接触角测量仪对PEEK和NP组材料的亲疏水性进行表征结果如图3所示,从图中可以看出,处理前后材料表面水接触角PEEK材料亲水性最佳,处理后的材料表面亲水性减弱。
傅立叶变换红外光谱如图4所示,从图中可以看出处理前后材料表面官能团的变化,NP组除与PEEK组相似的C=O以及C-O-C等基团外,在1255cm-1波长处有O=S=O基团的红外特征吸收峰;在1050cm-1波长处有S=O基团的红外特征吸收峰,NP组在1350cm-1和1500cm-1波长处有NO2基团的红外特征吸收峰,该结果可看出经磺化和硝化后PEEK(即NP)主链中引入磺酸及硝酸基团。
实验例2体外细胞实验
将原始的PEEK材料与实施例1中制得的NP材料分为两组,分别为:对照组(PEEK)、磺化后硝化组(NP),在体外细胞实验中,采用DAPI染色、黏着斑蛋白(vinculin)染色、CCK-8检测、碱性磷酸酶(ALP)染色、茜素红(ARS)定性定量检测等实验方法,分别研究了各组材料表面形貌对骨髓间充质干细胞(BMSCs)早期粘附、细胞形态、增殖、矿化等生物行为的影响。
bmscs培养1,4,7,14d增殖检测如图5所示,SEM下bmscs培养4h的形貌如图6所示,bmscs培养4h后DAPI染色图如图7所示,bmscs培养4h后DAPI染色图如图8所示,CLSM下bmscs培养2h、4h、24h如图9所示,bmscs培养2.4h后Vinculin蛋白表达如图10所示,bmscs培养7d、14d碱性磷酸酶染色图如图11所示,bmscs培养7d、14d碱性磷酸酶染色染色定量如图12所示,bmscs培养21d茜素红染色图如图13所示,bmscs培养21d茜素红染色定量如图14所示。
由上图可以看出,细胞实验结果显示,NP组表面BMSCs早期粘附数量显著多于PEEK组(P<0.05);PEEK组表面部分BMSCs呈球形未完全铺展,伪足数量较少;NP组BMSCs铺展较好,呈多角形或星形,伪足丰富,NP组表面细胞粘附更为紧密。在激光共聚焦显微镜下,2h时可观察到PEEK组表面细胞骨架及黏着斑蛋白未发育完全,NP组细胞微丝及应力纤维均已发育完全,黏着斑蛋白也相对清晰;4h时,各组细胞骨架均发育良好,NP组观察到双核细胞的出现,PEEK组细胞体积较小,细胞铺展不足;24h时,NP组与PEEK组相比细胞数量明显增多,形貌更类似成骨细胞。CCK-8结果提示4、7、14天NP较PEEK组细胞的增殖量显著增加(P<0.05)。ALP染色结果提示:7天和14天时,NP组ALP染色最深,呈蓝黑色;PEEK组染色浅;ALP定量结果与颜色结果一直(P<0.05)。茜素红染色(ECM)结果提示:NP组与PEEK组相比材料表面矿化结节明显且数量增多;ECM定量结果与颜色结果一致(P<0.05)。
实验例3分子实验
将原始的PEEK材料与实施例1中制得的NP材料分为两组,分别为:对照组(PEEK)、磺化后硝化组(NP),研究了各组材料表面形貌在对骨髓间充质干细胞(BMSCs)成骨分化的影响,利用实时荧光定量PCR(qRT-PCR)或Western blot技术对ALP、骨桥蛋白(OPN)、Ⅰ型胶原蛋白(COL-1)、骨形态发生蛋白-2(BMP-2)及转录因子RUNX2的表达进行检测。
其中,bmscs培养7,14d相关成骨基因的表达检测如图15所示,bmscs培养7,14d相关成骨蛋白的表达如图16所示,分子实验结果显示,qRT-PCR结果显示7天时,处理组与PEEK组相比ALP、RUNX2的表达量均显著增高,差异有统计学意义(均P<0.05);14天时,处理组与PEEK组相比ALP、RUNX2的表达量略增高,OPN、Col-1表达量显著增高(P<0.05)。Westernblot结果提示:7天、14天PEEK组RUNX2、OPN、BMP-2蛋白表达量均低于处理组。
实验例4体内实验
将原始的PEEK材料与实施例1中制得的NP材料分为两组,分别为:对照组(PEEK)、磺化后硝化组(NP),在体内试验中,将处理前后PEEK棒植入到大鼠股骨内,观察处理前后PEEK棒在体内的成骨性能。
其中,MicroCT大鼠体内不同植入体周围新生骨体积如图17所示,大鼠体内不同植入体周围新生骨硬组织切片如图18所示。
由上图可以看出:MicroCT结果提示NP组与PEEK组相比在植入后4周的骨体积增加了约17.61%。8周时NP与PEEK组相比骨体积增加约44%。硬组织切片结果提示在8周时,一些骨与PEEK直接接触;然而,骨和植入物之间有明显的间隙。NP组样品显示直接骨植入结合,同时植入物周围有较厚的新骨包绕。
上述具体实施方式仅是本发明的具体个案,本发明的专利保护范围包括但不限于上述具体实施方式的产品形态和式样,任何符合本发明权利要求书且任何所属技术领域的普通技术人员对其所做的适当变化或修饰,皆应落入本发明的专利保护范围。
Claims (6)
1.一种改性聚醚醚酮的制备方法,其特征在于:包括如下步骤:
(1)将医用级的聚醚醚酮材料制成10mm×10mm×1.0mm/15mm×15mm×1.0mm的方形试件或直径为2mm×5mm的柱状试件,依次用600#、800#、1000#、1200#、1500#、2000#、3000#、5000#、7000#的SiC砂纸逐级打磨、抛光;
(2)将步骤(1)中打磨、抛光后的试件依次用丙酮、无水乙醇、去离子水进行超声清洗10min,用烘干仪干燥10-15min,自然将至室温;
(3)将步骤(2)中干燥后自然降至室温的试件放入采用磁力搅拌器搅拌的浓硫酸中反应5-8min,得到磺化的聚醚醚酮SP试件;
(4)将步骤(3)中磺化的聚醚醚酮SP试件取出放入硝酸中,于16℃下反应50s,得到磺化后硝化的聚醚醚酮试件NP;
(5)将步骤(4)中制得的聚醚醚酮NP试件放入去离子水中浸泡5min,然后再将其放入100℃下的水中,水浴浸泡4h,即得改性聚醚醚酮;
上述步骤中聚醚醚酮改性过程的反应方程如下:
2.如权利要求1所述的一种改性聚醚醚酮的制备方法,其特征在于:所述步骤(1)中依次用600#SiC砂纸打磨30s、800#SiC砂纸打磨50s、1000#SiC砂纸打磨70s、1200#SiC砂纸打磨90s、1500#SiC砂纸打磨110s、2000#SiC砂纸打磨130s、3000#SiC砂纸打磨150s、5000#SiC砂纸打磨170s、7000#的SiC砂纸打磨190s。
3.如权利要求1所述的一种改性聚醚醚酮的制备方法,其特征在于:所述步骤(2)中丙酮、无水乙醇、去离子的用量均为每个试件1ml。
4.如权利要求1所述的一种改性聚醚醚酮的制备方法,其特征在于:所述步骤(3)中浓硫酸的浓度为95-98%,浓硫酸用量为20ml。
5.如权利要求1所述的一种改性聚醚醚酮的制备方法,其特征在于:所述步骤(4)中硝酸的浓度为78-84%,硝酸的用量为20ml。
6.如权利要求1-5任一所述的一种改性聚醚醚酮的制备方法制得的改性聚醚醚酮在口腔科和骨科植入材料领域的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811345142.6A CN109485896A (zh) | 2018-11-13 | 2018-11-13 | 一种改性聚醚醚酮的制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811345142.6A CN109485896A (zh) | 2018-11-13 | 2018-11-13 | 一种改性聚醚醚酮的制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109485896A true CN109485896A (zh) | 2019-03-19 |
Family
ID=65694830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811345142.6A Pending CN109485896A (zh) | 2018-11-13 | 2018-11-13 | 一种改性聚醚醚酮的制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109485896A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113527749A (zh) * | 2021-07-15 | 2021-10-22 | 山东大学 | 一种在聚醚醚酮表面制备多尺度多孔结构的方法 |
CN113633438A (zh) * | 2021-08-16 | 2021-11-12 | 宁波慈北医疗器械有限公司 | 一种表面改性人工颅骨修复体的制作方法 |
CN113750290A (zh) * | 2020-06-03 | 2021-12-07 | 深圳先进技术研究院 | 聚醚醚酮复合植入物及其制备方法和应用 |
CN113769165A (zh) * | 2021-10-27 | 2021-12-10 | 广东工业大学 | 一种磺化聚醚醚酮基骨修复复合材料 |
CN115382017A (zh) * | 2022-08-16 | 2022-11-25 | 兰州大学 | 一种可载药的新型3d打印聚醚醚酮种植体及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104497344A (zh) * | 2014-12-29 | 2015-04-08 | 中国科学院上海硅酸盐研究所 | 一种对聚醚醚酮表面进行改性的方法 |
US20160053042A1 (en) * | 2012-12-26 | 2016-02-25 | Universidad Del Pais Vasco/Euskal Herriko Unibertsitatea | Modified Polyaryletherketone Polymer (Paek) and Process To Obtain It |
-
2018
- 2018-11-13 CN CN201811345142.6A patent/CN109485896A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160053042A1 (en) * | 2012-12-26 | 2016-02-25 | Universidad Del Pais Vasco/Euskal Herriko Unibertsitatea | Modified Polyaryletherketone Polymer (Paek) and Process To Obtain It |
CN104497344A (zh) * | 2014-12-29 | 2015-04-08 | 中国科学院上海硅酸盐研究所 | 一种对聚醚醚酮表面进行改性的方法 |
Non-Patent Citations (1)
Title |
---|
李艳华: "聚醚醚酮表面亚微米结构对骨髓间充质干细胞成骨分化的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750290A (zh) * | 2020-06-03 | 2021-12-07 | 深圳先进技术研究院 | 聚醚醚酮复合植入物及其制备方法和应用 |
WO2021243979A1 (zh) * | 2020-06-03 | 2021-12-09 | 深圳先进技术研究院 | 聚醚醚酮复合植入物及其制备方法和应用 |
CN113527749A (zh) * | 2021-07-15 | 2021-10-22 | 山东大学 | 一种在聚醚醚酮表面制备多尺度多孔结构的方法 |
CN113527749B (zh) * | 2021-07-15 | 2022-08-02 | 山东大学 | 一种在聚醚醚酮表面制备多尺度多孔结构的方法 |
CN113633438A (zh) * | 2021-08-16 | 2021-11-12 | 宁波慈北医疗器械有限公司 | 一种表面改性人工颅骨修复体的制作方法 |
CN113769165A (zh) * | 2021-10-27 | 2021-12-10 | 广东工业大学 | 一种磺化聚醚醚酮基骨修复复合材料 |
CN115382017A (zh) * | 2022-08-16 | 2022-11-25 | 兰州大学 | 一种可载药的新型3d打印聚醚醚酮种植体及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109485896A (zh) | 一种改性聚醚醚酮的制备方法和用途 | |
Caetano et al. | 3D-printed poly (ɛ-caprolactone)/graphene scaffolds activated with P1-latex protein for bone regeneration | |
Ilyas et al. | Amorphous silica: a new antioxidant role for rapid critical‐sized bone defect healing | |
Wu et al. | Functionalized TiO2 based nanomaterials for biomedical applications | |
Gerritsen et al. | Biocompatibility evaluation of sol–gel coatings for subcutaneously implantable glucose sensors | |
Böke et al. | Plasma-enhanced chemical vapor deposition (PE-CVD) yields better hydrolytical stability of biocompatible SiOx thin films on implant alumina ceramics compared to rapid thermal evaporation physical vapor deposition (PVD) | |
KR101986089B1 (ko) | 표면에 칼슘을 포함한 임플란트와, 이 표면에 칼슘을 형성하기 위한 임플란트 표면 개질 방법 | |
US20020037383A1 (en) | Self-assembled thin film coating to enhance the biocompatibility of materials | |
JPH11510469A (ja) | 生体用材料 | |
US10907124B2 (en) | Biomimetic membranes, methods of manufacture and uses thereof | |
Li et al. | Improved osteoblast adhesion and osseointegration on TiO2 nanotubes surface with hydroxyapatite coating | |
KR101271721B1 (ko) | 다공성생체활성유리를 포함하며 하이드록시아파타이트 및/또는 콜라겐이 코팅된 경조직 재생용 지지체 및 이의 제조방법 | |
TW201240682A (en) | Non-woven fabric containing bone prosthetic material | |
Wen et al. | Strontium delivery on topographical titanium to enhance bioactivity and osseointegration in osteoporotic rats | |
Yakufu et al. | Covalently functionalized poly (etheretherketone) implants with osteogenic growth peptide (OGP) to improve osteogenesis activity | |
Zhang et al. | Endowing polyetheretherketone implants with osseointegration properties: in situ construction of patterned nanorod arrays | |
Li et al. | Magnetic silicium hydroxyapatite nanorods for enhancing osteoblast response in vitro and biointegration in vivo | |
Hanawa | Surface treatment and modification of metals to add biofunction | |
CN110279890A (zh) | 基于脂质体的地塞米松/米诺环素在peek表面的修饰方法及应用 | |
Yuan et al. | Functionalized 3D-printed porous titanium scaffold induces in situ vascularized bone regeneration by orchestrating bone microenvironment | |
Ilyas et al. | Rapid regeneration of vascularized bone by nanofabricated amorphous silicon oxynitrophosphide (SiONP) overlays | |
Bishal et al. | Enhanced bioactivity of collagen fiber functionalized with room temperature atomic layer deposited titania | |
Valencia–Lazcano et al. | Enhancing surface properties of breast implants by using electrospun silk fibroin | |
Liu et al. | Construction and osteogenic effects of 3D-printed porous titanium alloy loaded with VEGF/BMP-2 shell-core microspheres in a sustained-release system | |
Brammer et al. | Highly bioactive 8 nm hydrothermal TiO2 nanotubes elicit enhanced bone cell response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191029 Address after: No. 301, unit 3, Building 29, No. 46, normal road, Tianqiao District, Jinan City, Shandong Province Applicant after: Chen Lei Address before: 250000 1/F, Block A, Shandong Triumph Business Center, 142 Lishan Road, Lixia District, Jinan City, Shandong Province Applicant before: Shandong Triumph Mayo Oral Clinic Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190319 |
|
RJ01 | Rejection of invention patent application after publication |